<SEC-DOCUMENT>0001144204-14-049143.txt : 20140813
<SEC-HEADER>0001144204-14-049143.hdr.sgml : 20140813
<ACCEPTANCE-DATETIME>20140813105017
ACCESSION NUMBER:		0001144204-14-049143
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140813
FILED AS OF DATE:		20140813
DATE AS OF CHANGE:		20140813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		141036187

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v386663_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.
20549 </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month of August, 2014 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File
Number </B>_________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Novogen Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>(Translation
of registrant&rsquo;s name into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>16-20 Edgeworth David Ave, Hornsby, NSW
2077, Australia </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive office)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Novogen Limited </B>(Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Lionel Mateo </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lionel Mateo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date 13 August  2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v386663_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">
<p style="text-align:center"><b>Novogen Announces Results of General Meeting of Shareholders</b></p></div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>SYDNEY, Aug. 13, 2014 /PRNewswire/ -- Australia-US biotechnology company, Novogen Ltd. (ASX: NRT, NASDAQ: NVGN), an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia. A total of 28.3M shares were represented in person or by proxy at the meeting, during which the following resolutions were passed (95% in favor):</p><p><b>RESOLUTION 1.  SUBSEQUENT APPROVAL OF ISSUE OF CONVERSION SHARES
<br /></b><i>&#34;That for the purposes of Listing Rule 7.1 and for all other purposes, subsequent approval is given under Listing Rule 7.4 to the allotment and issue of the Conversion Shares as described in the Explanatory Statement.&#34;</i></p><p><b>RESOLUTION 2.  APPROVAL OF ISSUE OF NEW SHARES AND ATTACHING WARRANTS
<br /></b><i>&#34;That, for the purposes of Listing Rule 7.1 and section 50.1 of the Company&#39;s Constitution and for all other purposes, approval is given to the increase of the capital of the Company through the issue of up to 80 million New Shares and up to 80 million attaching Warrants in order for the Company to raise up to approximately $20 million on the terms described in the Explanatory Statement.&#34;</i></p><p>Graham Kelly PhD, Novogen Group CEO and Executive Chairman, said, &#34;These two resolutions are about providing the Board with the capacity to raise the working capital Novogen needs to bring up to 3 drug candidates into the clinic. The approved resolutions now give the Board the flexibility to tailor capital-raisings to specific requirements according to when the capital is required and in response to market conditions.&#34;</p><p>&#34;The first product we need to
support is Cantrixil, the outcome of the Novogen-Yale joint venture company, CanTx Inc. We currently are making this product ready for the clinic with the aim of conducting a Phase 1 trial in women with late-stage ovarian cancer in the US by mid-2015.&#34;</p><p>&#34;The second product is Trilexium, a drug candidate being developed for the treatment of neural cancers such as glioblastoma and other primary brain cancers in adults and children. This is part of a global initiative known as MINDTrx (Multi-Center Initiative for the Development of Trilexium), and is being prepared to enter a Phase 1 trial in patients with glioblastoma in Australia, again by mid-2015.&#34;</p><p>&#34;Our anti-tropomyosin (ATM) drug program has progressed quicker than we had originally predicted and is presenting an exciting opportunity to move it into the clinic in 2015. Whereas the super-benzopyran drug
candidates are exciting because they present for the first time a realistic opportunity to treat cancer in its formative stages, the ATM drug opportunity is about comprehensively destroying the cytoskeleton of the cancer cell to a degree not previously achieved, arguably delivering a potent cytotoxic effect across a range of common cancers. This will be the third drug to enter the clinic, with late-stage prostate cancer the targeted clinical indication,&#34; Kelly added.</p><p>Immediately following the General Meeting, an Open Briefing was held for shareholders and the general public outlining the Company&#39;s R&amp;D, clinical and growth strategies. The Open Briefing was video recorded and will be available on the Company&#39;s website by close of business on Monday 18 August.</p><p><b>About Novogen Limited</b></p><p>Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange (&#39;NRT&#39;) and NASDAQ (&#39;NVGN&#39;). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.</p><p>Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to have a uniform cytotoxic effect against both cancer stem cell and are being developed in the first instance for the treatment of ovarian cancer, neural cancers (glioblastoma, neuroblastoma) and prostate cancer. Cantrixil and Trilexium are SBP-based drugs. ATM compounds target the microfilament component of the cancer cell cytoskeleton and are being developed for the treatment of melanoma, neuroblastoma and prostate cancer with the rationale that a combined attack on both key components of the cytoskeleton (the microfilaments and the
microtubules) delivers a comprehensive and permanent destruction of the cytoskeleton.</p><p>Further information is available on the Company&#39;s website, www.novogen.com.</p><div>
<div><table style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt" id="convertedTable188c" border="1" cellspacing="0" cellpadding="0"><tr><td colspan="2" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">For more information please contact:</font></font></p></td></tr><tr><td colspan="2" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td colspan="2" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>Corporate Contact </b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>Media enquiries</b></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Executive Chairman &amp; CEO </font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In the USA:</b></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Novogen Group </font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN:
bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Graham.Kelly@novogen.com</font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Lazar Partners</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+61 (0) 2 9472 4100</font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Novogen@lazarpartners.com</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+1 212-867-1762</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>Investors enquiries </b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In Australia:</b></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In the USA: </b></font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Dr. Douglas Pretsell</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Instinctif Partners</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Lazar Partners </font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font
style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+61 (0) 3 9657 0706</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Novogen@lazarpartners.com</font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+1 212-867-1762</font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In ROW:</b></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Sue Charles</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Instinctif Partners</font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">
<br /></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 6pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+44 (0) 20 7457 2020</font></font></p></td></tr></table></div></div><p> </p><div style="TEXT-ALIGN: left; WIDTH: 100%" id="prni_dvprnejpgcdd3left"><img src="ny36990logo.jpg" id="prnejpgcdd3left" title="Novogen Logo." border="0" alt="Novogen Logo." align="middle"></div><p>Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO </p>
<br /><br /><p>
</p><p> </p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ny36990logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ny36990logo.jpg
M_]C_X``02D9)1@`!`@```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`0$"`0$!`@("`@("`@("`0("`@("`@("`@+_
MVP!#`0$!`0$!`0$!`0$"`0$!`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@+_P``1"`"3`9`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBD)P,
MX)^E&XFTE=Z)"T5`TVUU7RY&W#.X`$9YXQG/0'GI[U*'![$>QP"/KD]:7,K7
MOHBK/3^]JAU%,,@`SC]0/Z\4TS+M+*"X']WGCN1Z_A36JNMD)Z)MIV7DR6BH
MHI5E!*@C:VT@C!R*EH#U37JK/[GJ%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%(Q`'/.?\"?Z4M13,JKEFV@Y&<XQE6&3[#.?PI./
M-IW$W97>B1YE\7OBCX3^#'PW\=?%/QWJ=OI'@WX?^%M4\5^(M0FR1;Z;I=I=
M7D@CC4YGG=K<Q11KEI99EC523@_Q:>(_^#D3]M*X\0:Y-X7\#_!?3/#3ZOJ)
MT#3M7\+:SJ.JV&D?:YA86FJ7]OXHBCO-1CMA&D\D<<<;RJS)&BD*/LW_`(.,
MOVWY;72_"7[$7@#66AGU<Z9XY^-M[9SR+):::'2?P3X,FEA8#SIKWRM4N8CP
M8;&UR2DCJW\CJLS@.V4=\M*BLVU)F.Z:-3GE%E+@>RC/-?E'&/%F.P^/67Y9
MBOJ\*.LI0UDWHK-[:?F?Z0_19^CKPOFW!.)XN\0<@AFU7/JD98"AB5-*&"LW
M#$12<'^^G&2A9M>SBFTFU?\`?S_B(^_;P_Z%7X##/?\`X0K7Q@GW_P"$OXYK
M8T'_`(.2?VV;36](O/$?@7X)ZSX>M=1LIM=TO3/"^M6&JZAI*7$9O['2[V?Q
M4ZVNHRV_F)!*R.D4CK)(CHC(W\]O/]YO^^F_QIC[PKE6.[:Q&YB5!"G`()[G
M`XZEJ^0CQ5Q`I4YO-:CE%ZJRM;3SWW/Z=J?1S\$9TZD7X=9?-UHS@^:-6T.:
M-HU(6K*\XRUL[*R6NY_JP_!7XK>#?CC\+?!'Q=^'VK1:WX,^(7A[3?%'A^_B
MW!FLM3MUF-M<QN=T%]!.9H+B)L-%-;R1D`K7J5?R3?\`!N?^V^AC\5?L1^.M
M8<W4#:KX\^"M[>S2#[396QA;QOX-*32?+<0RO%?V@7Y3&U^2"5%?UF(6VE?-
M;."RLQ))0XVDG'4`<^YK]QR',HYQEM#%J5ZCBN=.R:DM]%=6[>35]3_(GQ9\
M/<;X7\=YWPCBN:I0P<E5PU9Q<57PE5WIU(\S;:A=PGKI*,K75F7:*0=!WX'/
MK2UZQ^<!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%>"?M/
M_'3PS^S1\!OB=\=_%UK>7^A?#/PKJ/B2XT[3U9KS5;JWC$6F:3`RJ1"]UJDU
MG!YKCRH1.992(U8U[W7"?$WP#X2^*?@/Q5\.?'>D6>O^#_&NA:GX;\1Z-?KO
MMM1TG5K.6SO;8@$%)3!*YC=2&CD574@J#45%.5.I&F^6HXM1>^MG;\3ORN>`
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MBEHY5@$L3O&RL?\`-M_8W_9D\4?M?_M(_"_X!^%UG@;QIKF_Q#K4(/\`Q37@
MK14CU/QGKID\MEC\G1(Y&0,`TMS':11!MTA3_06^/?QS^$?_``3E_9J\(-8^
M&#-X=\*V_A[X=?#CX?:1=VNF:AK#VED-\-M<R1LJ&+2K&>[NYO+=<MDYDE56
M_7_"[!9GB:N+H4:<JM'$65)6O>K>SBO*VK^]L_S,_:%<3\#9%A>%L5F]>.`X
M@RC#8K%8NNW"U/*+J%/VUES-SKJ7U>%^91IU='SQ/OGSH1QYB<<?>';\:/.A
M_P">J?\`?0_QK^>C_A_KX(_Z-K\7=_\`FH&B?_*3BD/_``7T\%$87]FWQ<IS
MU_X6!HAY'TT48%?NO^HO%=[?V1-7[N%NG]X_R7C])+P6T2XXPKO9))5KZVM:
M])+\?F?T,>?%D#S%)/H0?Y5*#D9'^'\Z_(G]C[_@J_\`#S]JSXKQ?"B?X?ZU
M\--<U+2K^_\`#MSK7B#3]9L]>N]-59[W28&M;6(Q7HL#-,H(*LMNR[@[(K?K
ME$VZ-6]<Y]CDY'MSV[5X69Y7F&3XI8/,,)+#5>7F]ZW5VLK?/576A^G<+<7\
M/<:9=/-.&\PCF.#I3]G*<>D[7M9ZK374DHHHK@/I0HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`J*50RC)VD,"K#&5;!P1N4\_A4M,D^[DYP""<#)X]!WY
MQ4RNE=;IK\T#O]G5]#^<W_@X,_8=_P"%V?`;3_VFO`VC/<_$GX`V\S^*_L$8
M-[X@^$TSM_:T4H1,R7FDW%PVH0R$E([9;T212[H3!_$%R22IC8,S-O161'+$
MLTB(68QHS$L%+,RAMI8D$U_K&:WHFEZ]I>K:'K-I%J.DZW97NDZMIUW`MQ::
MCI^J6LUG=6$\$@*RP26\\JNI!5E;!%?S5^(O^#97]G_6?$&MZMHW[1OQ8\,Z
M5J>JW]_IWAVT\)>$]0M-#M+NYDGATJTO;V02W%K`CB.,R#<$0*2<9K\XXOX3
MQ>/QWUS*J$93KV=57M>25N=WZVTTZ>;/[R^C1])GAK@7A#$<%>(&95<+E^45
MI2RRO&C6KSG"L[XBC+V-.I)1I54G!R25I<J=D?QC_-WQ^'<]AS43/(`2`HPK
M_,P8JIVD)D`_,/-*?*,%_N`JS!A_9*?^#8/X(\X_:G^+^><?\4/X*(_2;I6I
MX=_X-EOV?](\1Z%J?B#]H_XL>(=#TW6-.U#5O#ESX5\(Z=!K^GV5W'<W>CW%
M_;2>;8P7$,3QR2QYDC61F3!`-?*TN!,^J2@JU"-*/-JTU>VE^NWIJ?T?6^F)
MX(4J=2K3XCQ,JF&C.<(_V=BI*M4<;0I2=2E3:CS6>R6OQ=%W'_!OE^Q/!\'_
M`(#ZO^U/XUTI8O'?Q[M4A\)2WBJTNC?"#3[PW&G+:^9"OD-K%];_`&Z>0_Z^
MVM+(!412K_G]_P`%1_VJI/VD_P!HS5=$T/4Y+SX:_![[=X-\'6\<N8-2UF+S
M(_&WB145SYCW&IV-E:K)D'R=*01[0[F3]YO^"E_[2>D_LD_LM#P)X%73]#\7
M_$'1W^&OPZT33W6T7P]X=L=/M=/\1:K9+"J"TM;'1;B&RMY@NV*[U>R(&.G\
M=A+*Q.Z5W5BKRSJ4N&D23>YG#$LLYF!9PQ)WYSWK^Q/![A.&4X&EF%:DH4\/
M^ZI3Z^W=FZB\[Z:^?2Q_SA_3^\?\U\0^,<9E,Z\X8K.JT<5CH+W50I4$HY?@
M^1W4:<Z#G5E!/E<H\SU;&$C)X!YZY//OUHSZ`#OD9SQ^-)17[Q=]9-_,_P`X
M7:WO:I=]5TMIMHTGMT.L\"^-?$?PX\8^%_B!X1NI++Q+X,U[3/$>BWD1S+#J
M&EW27T&4)_>PLUJ%DC/R2H624.IVU_>#^S-\>]$_:,^"G@#XL^&Y;3[/XHTV
M-M4M(PP.FZW:N;/6]-:(SL89(]2AN`@9V;RY8F8N2<_P)#@Y!((*MP<<KN"G
MZC>WYU^V?_!&']JA_AK\6K_]GKQ5JBCP9\6[N.^\)17,H5-#^(5A!##!%;*7
M^6WU738KN!QCYKNUL\`$N6_//$3(O[4RQYC2AS8O`OFE._O.E:THZZ:.TEI?
M2R/Z5^B[XDRX0XPI\,9M4>&R+BN?(ZE_=AB])4))6T=64?J[LDK5+M72/ZP`
MS;L<$<#([]<U+4$94L,,#G)QGMDC/XDU/7\]/TL?ZAQT5F[M;^3ZKY;!11D>
MHHI#"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*:_*D'CW'4<]:=4,\GE(&Y^\`
M.G4G"CD]2Q4#W(S0WRZ]A2U5K<R>EN]]#"U?5=/T>POM7U6ZAL-,TNWN[_4K
MZZF6"ULK+3X&O+J^NIY&"PVT=O$[2.3M5%)8@<U_'W^T9_P5,_:7\6?&KX@:
MQ\'OBUXB\$?#5M7>P\&:!I,-C':1:1I*3VD&I327MM(YO;V\"W,@*#;$51@'
M!4?K3_P68_:R;X6_"&U^`OA34O(\=?&&.9/$20S^7/I?PTBE:+51,B9*G4Y(
MIK+;@;[;[5N9?W8?^4=@49H_N^63$`&+#;$3$I#D`R91%.X@%LY8`DU^R^'7
M"^&K8*MFV8X*.(C6_=PA/5:-2<T^^C2\DNY_`7TI?%S-,-G^`X'X8SC$996R
M->VQV(PM6K2E5JU(VHT7*C*,FJ-.4G.+=N=KJE;[D_X>4?MPG.?VB/&Y'IG2
M.1[_`/$OJ-_^"D?[;C$;OVAO&Z<'F,Z-YIRI&$+:/)\V2,<IROW^Q^'LGOS[
M')%`(!.1V.WV;UP?:OTE</Y&N:V2T+S7+MLN^W_!T/Y1_P"(@\>SC/GXPS&H
MZ?+*//CL9=R33Y5^\>FG^1^Z/Q6:Z_X*)_L`V'QL$ZZS^TG^R9-<Z5\1!#''
M:W_B7P;+:O<7NJ_Z*BLT,]G&-3BD5<QOIFI(B>:VQOPP."[K&`(P9C$JQ"W5
M887*JBP#B+9&%&P<H1M(!!`^Z?\`@GE^TY_PS+^T-X?U/7[B,_##XC(WP\^*
M%C=@2Z?)X=UR6&SL]5NK:0&.?[#J]W92G>,BWDN8ERD\P6I_P4#_`&:6_9D_
M:+\1^']'MV7X=>-$?Q_\+;])/.L9/"^MZC*LMC;7F2LAL+YS;N&)D:(PW)W)
M(7KR\G<\IS.MP[*U/"UI.OE[O[L)Z<U%.VZ;OKI:7D?:\<SI\<<)Y/XAX93K
M9SA:U'+,[BY2J3^L48\^"S"I.=Y1H8FAS8:O.;7[^%*_<^'NM%%%?6MI)MSC
M)K=1DI/SM&+<G\DV?CK<4KN48KSE%)?.XA(498[1ACN/"X39N^8\`_.O'4YX
MK]3?^"6OP&T?QG\6==_:"^(XBT_X-_LS6*>.?$VLWBN=/F\2VEE<ZCH5DR*C
M"^FM8[6>]E6,.ZK:VB$"22-&_,?1='UCQ'JNG>'O#VGRZOKNMZE8:3H^DP1^
M=-J&JZI)+8:7:Q1G@O)J,]JN3PH^9R$4FOVO_;?US1_V,/V3OAE^P3X$OXY?
M'WB^SM_'GQ\UBQ<F26XO9H98[6Z:(*;@:A?PI`B.H46&A*S%=P0_,<3XFI/#
MX?)L)+V>/SEQC";NG2I73J56K72<?W:V=YH_4/#'+\'1K9KQ]FE.-?(^!J;Q
M$97O3K9DG%8+#J<6TU[5JI6BKOV-.I;70\*^)/\`P5S_`&NO$/Q!\8:_\/O'
M[^!_!-_K-[)X.\+CPYX0U"XT?03=O!IMK?WM[X>D>XF.FQQ33_,W^E3N%8J,
MUQ?_``]>_;O_`.BX2?\`A&^!_P#YF*_.;'7UY[>X[]N?Y4E=5/A7ARFN2GE5
M*I&"BOWB3=U&*DT]=').7S/-Q7BWXDXW%XK%T^-LUHK%3=64(XF5%1G4M.:Y
M(W5KOW>O)96/T8_X>O\`[=R2+)_PN@3O&T4BI/X1\&B&4Q%W6WE6'PTK);N0
M!(RG=AUVCBOZL?V/_P!HG2_VG?@)X$^*FE36PO=0L'TKQ;IZS1/+I/BW1]MK
MJUI<1Q(GV;=,HGC78F8+V)E!5E)_@WST]O\`/I]/RK]?O^"/G[4LGP8^.TGP
MA\0ZH\'P_P#C7<6^FVL,\H6STOXD1VIBT/5(XV4A);VWC33IN0)#':M)_J%S
M\AQOPE@:N43QF4X"CA,5@6](I^^K:Z+U37FC]K\`?&_/\LX^P65\8<08G-\H
MXGBL%%8NHZBH8E/F5=U'>Z?PO;?R/Z]I%+1N@8H74H&7!*EAM#`'N"<_A7\J
M?_!43_@HS^VO^S]^VOXW^#7P'\>II7A#1?!O@[Q%9>&X/!'ACQ!?K]K\&67B
M+Q!)#<:G8RRS%8(KV38@+`'<K80@_P!4RW"N0N""<'.1CY6VL.#R0P((]J_D
MK_:X6.?_`(.`?A-;S11S6]YXB^"=C=0SQ)<6\]G?_#F&RO+:ZM95*75M-:SR
MQ/&_R.LQ5N.:_`E)/FL[N+L_)]OQ/],(^\KI65KZIK3RO:_R/V3_`."3?[;6
MH?MF?LWQZKX[U6PU#XR?#K6)_"?Q+DLX;&QCU&5E:\\.^)K?3[*&-+;3[_2Q
M(J%5*M<:1=X.$-?J2"&&1T.?8\'!!'8Y'3J.AK^/7PM<7'_!'O\`X*O7_AV4
M7.B_LQ_&VXBL4@<S/I5I\-/&VHW=]H=U&S*3<R^$/%=K'91R,S21Z>+E6=FO
MR&_L!MYHWMX7C82HT,,BO%*)XWCE4,LT<_'VB(J<AQ]X<]ZH#\#/^"V?[;'[
M1?['C_L^K\`_&UKX+C\<-\1)/$PN?#>BZ_\`V@/#[>%1IH0:E"QM0D=_>_,I
MS\G3[N?V^^%VL:CKOPW^'NNZO/\`:=4USP/X3U?5+E8HHDN-2U30M.O;RX$,
M"!81)=SW#;0-J^PK^9/_`(.5OO?LI?\`7+XO?^B_"=?TG_">[M;#X)?#&_O[
MF&SL;'X6^";R^N[EUCM[:RM?"=E/=SSRN,10K;I*S,2`JJ22*`/`_P!MK]NK
MX,?L-_#A?'7Q-O+C4M=U;[5:^"?A]HQC/BCQAJ5M"9)1;I,P72=$M]\/VO4;
M@""$W,4,?F74\,$GX#Z1^V[_`,%EOV[KR^U3]EWX:_\`"J?AI'=3V4&M:7H>
M@Z3H_$I58I/'OQ$=WUN^5MP;^R_+))_U*]_%_@%X9O\`_@LE_P`%,/&7Q+\?
M_P!HW?[/OPT>7Q)%I,DDL$/_``K[2]433_ACX4`^;[!/KMS;7=WJ20X!CEOF
M9GDBM-O]BOAOPMHGA+1='\->&=*TK0/#>A:9;:3I&AZ/8I8:?IMC9QK%;6]A
M;02".UMTB10%"%AU,A/)`/Y:=?\`AA_P<._#6U?Q5%X^U'QLMBC7+Z+H/B_X
M;>+[AXE4R3(FAZP+#<^0`$22Y9R=JHS8%>@?L?\`_!<GQQIOQ(M/@-^WQX&B
M\!:ZFK6OAU_B3;Z%JGA6^\.:K>M';6L/Q&\%7D'^@6LLY96O[40Q1B59?*DA
M+2I_3PP)!`)'3H<'@Y(SVST]>>*_$_\`X++?L%>$OVAOV?O%?QM\,>';&+XW
M_!S0KKQ)!J]G9QFY\9>"M*AFG\1>%_$4*I_Q-H(M*#W%N\I>5&TT(KJK;:`/
MI?\`X*6?$GXY?##]CGQI\:OV:_&<7ASQ;X!F\->,[N_CTOP_XDTG5_`7]HVE
MEXA6)=7T^XM[BR33M92]2>)5+PZ<9%+#+'&_X)3_`+6GB3]K[]DGPYX]\>:K
M#K7Q1\+^(?$G@3XB7<=G8Z:UUKFDW$.H:9?SZ=IT4<-H\_AZ_P!*<B)!'O\`
M-`/F+(J_$_\`P18^-T7[6O[$/Q+_`&9/B;>/XGN/AKIMY\,YDU1WGFU+X3_$
M30+N+PRM_),&,ODHFL68."T<=HL:9\M:^,_^"''C37/V</VS/VD_V-_&]R]L
M=>EU:*SM[P.DEWX\^$VIZK`]Y"K`>5/>>$[S4I[@*N9&M(."%!4`_K7J.0@!
M00QW21@85FP=P()V@[5R.IP/>I*\L^-WQ1\/_!+X1_$7XN^*64:'\.O".N>*
M[R-G$9NVTJPFGM-/C8CBXN;P6]O%_P!-+E:`/Q`^._[<?[2_C?\`X*J_#G]C
M/]G#QW;>%OA_H=[X;M_BTR>&/#>LS3KI]O!XQ^($_P!LU73KB2VGC\.FUL(4
MB(VW$KD#+;C^N_[3G[5'P?\`V/?A1J'Q4^+^O?V=H-B18Z'HFFQ1WOB;Q3J\
MD?F6.@>&=,,ZB^U%H]O)*1('3?(N]-_X1_\`!!SX7^*?BQ\1_P!IC]O'XG1?
MVAXM\=^)]<\):!JDRQP@ZSXIU6U\8_$34;1&1FM'\N3P[8PJF1!;VT]NNT8#
M?*?QO;7_`/@K7_P5;@^!QUW5X/@)\(=9O_#J6VE7#0VND^!?!$]VWC[Q#IJ-
M&4AU_6=<M(M/2\(\RVBOK01[?(``!ZW_`,/(_P#@JI^WEXCU?3OV(/@S)\._
MAWI]W+8KX@L]*TK5YK>",A/*UOXC>/A;:-_:0PQ>'3X'N4S@PKG(U]1^#7_!
MPYX4M7\31?$J^\02P`S_`/".Z-X^^&&JW<VR-RD26.M6R6ID_P"F(C*DD*K[
ML*W].GPX^&?@GX2>$-`\`_#GPUI'@[P;X9L(M.T;P[HEL;:PLK6%0L:HJN#/
M<8"^9/+YDTY&Z1RW)[QAN&.@/7'!Q['M0!_*=^S[_P`%N?VA?@?\2XO@M_P4
M*^%]_:&&\M]+U;Q=9^%+CPMX[\,33/)''>ZWX620VOBC2C]EN"[V$5M(Z@_9
MTEVA7_J-\(^+?#7C?PSHGB[PCK5AXA\,^(],L]:T+7-+N/M>FZMI>IP1WEE?
M6%TI*W%O)#/&05+!6)C)W*0/SU_X*9?L&^#OVTO@+XEL(="LHOC1X)T+4=>^
M%/BZTM536YM8L;>:[?P9<72-YEQH>J10/:,DAD\BXU"&\@V2P8?\QO\`@WN_
M:?U_7-%^*G[(OCFY:6[^'#2>./AT+MP+W3-`N=5BTGQ=X16`X"Z?8^))8+BV
M"*`K:E=@K%&L*$M?Y`?T)?&?XU?#7X`_#CQ)\5?BMXGLO"O@OPM9"]U#4KO<
M[SR2-LLM.TVV12^H:I<7&V."",%W9LG:BLZ_S'^.O^"RO[<'[6'CW4_`?_!/
MWX%7]CHUO/Y%CJ\WAD>-?&T]M*Q2UU/7)KV:/1?"4$L;I)Y4TH:V9HXI)IO,
MR,#_`(*S_$'XA?MH_M\?"C]@#X?:Q>Q>&/"GB+P]I&JVEA,T-K>>/O$NGKKW
MB3Q7JZE'C>31/!QNVM5="D<LEPH7YU8_TL?LS?LS?"C]E3X9:'\*?A)X>L-'
MTG2;&W&KZO%:00:SXIUH*8]0\1:_>(C/?ZE=7,4LC*[F.$,L<0VYIM-;@?SM
M1>!?^#BO4HAKDGBG5;)W47`T>7Q/\$;*Y1L!O(^QV\,T"\DX1C(/60]![)^R
M_P#M!_\`!:3PK^T;\*OA%^TM\(YM;\`>-O$\.E>(_&OB+P5H,MGHNBPV[ZAJ
M>J6_CGX673V$=]'IL+I#]MAA9G=5,;%<G^DJ-!&I`QRQ/`0#G`Z(@]/<^],>
M$.'!Z.3GIP67RV8;E()\LL,%3GU%(#QG]I;Q?KOP^_9V^.WCSPO=?8?$O@OX
M0?$;Q7X?N_*@F^SZUX?\(ZOJNF2F&ZB>.11>VD.5=64C((K^5C]F3]KO_@MK
M^U[H7B?Q/\`_&&@>,=+\'ZU;:!XBOI=!^#WATV>JWNG6^HQ6L=KKNEQ&XC:S
M^SR>:NX_/M)!+`?U`_ME?\FC?M/?]D`^+W_J!:]7XD?\&VG_`"0S]I?_`++%
MX:_]0#2Z`.1Q_P`'&?\`?\._G^S[_P#(M?HM_P`$[$_X*<?\)7\37_;V_LIO
M#?\`PC^@CX<G3Q\/!)_;?]H79UG[0?!+!PGV0VY_>(BG'&6%?K%10!_/O_P6
ME_;8_:9_9(\4_L]:-^S_`.-H/#,?Q!T_Q<->M+CP_P"&=<.JWEE?Z-:Z6@?7
MM(DCLU_TMU:3>H42EL?+N.S_`,$=/^"CWQ,_:;UOXI?`?]IO6+:]^./@ZX?Q
M!X<U-=&TOPV=;\-1"VL_$&@W.DZ7;0Q1ZWI.J[9&.SS);?5"T@1H60?'G_!Q
MRYC\?_LBR!BIBT_QQ*K``L&CU7PZZ[5)P[9484D!C@$@$FO*_P#@H)\//&7_
M``3Z_;!_9X_;^^%.ER2>"_B3#X6UKQGIMFAAL6\;P^'M.B\>^%KUT6-8;?Q'
MX;CO;Y9"^'O([HS>2%A:0`_L%5@P)&>"0<@@@CL01_G.:_,/_@K7^T/\6?V8
M/V1M;^*7P:\11>&?&D'C?P;H4&J7&FZ7K$4.FZM=W,>H*;#5-.FCEW($`SD\
M\$8(/WW\*?B3X0^,7PZ\&_%/P!J<>L^#?'WA[2O%&@7Z#8[V&K6,-U''<QL=
MT5]&TC1SQN`\4T3QN`R&OR8_X+V?\F!>(?\`LI?P_P#_`$ODH`^PO^"<'QA\
M>_'[]C?X+_%KXGZO#KWCGQ;IFM7FNZQ;Z;::/%>W-IXAU?38Y%T^Q`C@'V>W
MCZ9]3R>/N>OS)_X(\_\`*.S]G'_L!^(__4OUZOTVH`*I:A*T%M)*L;R^6DC[
M(PID8I&SJ(PQYD+*`O(Y(Y'6KM5[I0\10D!7#*V02I#(PYQVIII--[)IO[S.
MJI.G.,7:4DTGV;5N9^4=WY(_@>_:R^./B[]H3]H+XD_$GQE8:AHE]>>(;S1[
M#PEJP<WO@[1=`GFTNR\+W>]ODOH%@;[:J;5^V&;:J@8KYO&<#)).`,G&>/7`
MK]K/^"S'[*G_``J_XP67Q\\,::T'@?XQSK%XBDM4CB@T?XBVUK*UY^ZB4`1:
MCI(DNLXRUY8R.<EC7XJ#=@;MH;`W*O1&P-T9]64Y4^I4U_5G#>-PF.R'+*V`
M@J6%]G9PTYHSCHT[:='^I_C+XG9%G'#OB#Q=E^?U)U\SJXN5;VLK\M6C.[I5
M*;>O)*+NK_,****]L^%$()5E!*AP58C'S*8Y8V7Y@1_JYY1Z_.""&"D?T2?"
M/X6^)/\`@I5_P3O\+>'/$PL_#OQ)_9]\9W'A7X>_$WQ=]J31==T.SMK".YT^
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MQ?7]G7ID#_A*/%6?8$'PAQ2-_P`$1OCJ.6^.O[.N!W'B?Q8VT=S@>#R3^`)K
M\9O[5U3_`*">H_\`@?=__'N:<-5U3!SJ>H]L?Z==]<''26NO^SN*J=ITN(Z<
M)JUG'"4XR5[)VE>ZTOTU/*CQ/X/0G"4?"G%)QE%WCQ!B(O1J]G]5DE=*VST=
MO,_HZ_9+_P""8NJ_LJ?$+6/VC_C#XJ\"_%.P^$7@_P`1^*/"'A?X8OK^OZE/
MXJLM-EG^V30:CX?MA)-#I270M(HR\K7-RDQ58X&63\"_CA\7_$WQ[^*_COXN
M>+Y9'UKQUK=SJK0>8WEZ3IY,D&D:-:-O.+6RTPPV\9_B\HR,`[-7T!^PG^U-
MJG[,/[0WA/QCJVJ7C^`/$CKX-^)MK<W%S<V]QX0U298IKV2%Y&23^S[^>SOC
MO!Q%9S!<;V#=K_P4I_9G@_9[_:"U+5O"ECY/PG^,L,_Q#^&M[9B.;2[>VU"8
M3:_H=@(SB.VT_4+^"1%``6SU6S1054&N/+*6+P'%-:EG.+CCL;BJ*6'K3NHN
M*:E*ERVM&;:4E;1J^NB/<XFQ>3<1>$^68G@C*I<+Y%D685WF^6JL\2Y5<1)1
MP>-J5W&G.I2BKT)J5.-JE6/*FFV?GIT_SU_^M_A24N1Z?YY[_E25]M'F<>>I
M!TJDV^:+W33MKTUM=>1^"J;J.=222DY.+MLW!\KMY:+_`(8*L6US<V4]M=V<
M\]K=VDJ3VES;32V]Q;3QSK<1SV\T#*T<ZS*K*P.Y3RI%0=!GWQ[?YYKV3X`?
M!7Q-^T)\7/!'PD\)YAU3Q?K$=C<7[0BXAT;2H5-[JNO7,989M;72XII'7.6.
MT#DBL,37IX;#UYUG%8?5SYMMM?P.K+\%CLQS'+LMP$)RQ6+K)87V?\66*NO=
MI]FE9ZV/[,OV!/CYKG[27[,OPX^)7BRUNH/%1MY/#OB.^E@%O!K^L>'F;2[O
M6[50NV2&Z:!9Y#%M5)Y9%`50$'X!_M7_`#_\'!'P8`8KN\7_``'4E<9^?P+:
M(2N0<$$Y&<\J.O2OZD?A;\,O"?PA\`^#?AIX)TYM,\+^"=&T[1=&MY)$EG>W
MM+;[.US=7(5?M6H32))<7,FT&2:Y9SC)`_EP_:P7'_!P7\%A@#'C/X"9QCOX
M&L_3W/ZU_)>.J8:MC,95PM)T</6FY0B[7BKZ+339;+0_VTX8PN:X'(,DP>>X
M[^T\VP>$C3Q-9IKVE9*-YQ5E==-4FUJ[:GZA?\%J/V.8_P!IC]EC4/'_`(6T
MD7?Q6^`<.J>.M`DME<:CJW@L0&Y^(/AB(QH6N%ETZWM[V"/*E;C0X]I8221O
M?_X(O?MAM^T[^RQI_@_Q1K"ZA\5O@#)I_@#Q8MQ(#J&J^'%MB/!GBLJ\I9K2
MXTN":S<M\ZW/A^<N?WB`?KU+;Q7=NUO/%'/#+"89X95#1SP3&,2V\BN"LD+Q
MHZNA!#`[3P37\?\`JZW'_!(7_@K&FK-Y^E?LW_'!FO)[I&<Z:GPZ\8ZRT5^)
M3%A4_P"$>\7W,<IW*3##IP*';>$'C/;/9?\`@Y6^]^RE_P!<OB]_Z+\)U^UO
M[0>MW/AW_@FG\2-7M"XN+;]D6YA0Q^8)`NH?#,:;,4:)U:,^1>2?,K!E!+*0
MP!'XE_\`!RA-%<Q_LF75M+'/!/;_`!9ECDAD6:.>&>T\(.L\+`_ZD-W[[A7[
M]>)_A[>?%G]A_4_ACINS^U?'O[,:>%-&\TA8AK>M?#7[%HK3,W"P#59;,OG`
MV@@D=0`?C)_P;>>'[*/X,?M'>,&1)=;UCXG>%]"N+LB/SOL&D>%1=P0D1H`D
M+7FJW<A5<+EOD"\Y_I0C4*@4#"KE5'HJDJHX[``5_*7_`,&X_P`7+'2=?_:*
M_9WUB8Z=KNL)H/Q*T+3+A2ET_P#8`D\*>,+(8_Y;6S7.@[SQR['M7]6JDE02
M`"1R!T#=Q^>:`'51U.PL]5L+S2]1MXKS3M2M;C3]0LYT$D%Y8WD$EO=VLZ$?
M/#)!(ZL.,AB,\U>KR[XV_%+0?@E\(OB/\7?$TBIHOPY\'ZYXMNXV<QF\;1[&
M:YM-+B<`XN+N]6WM8N/]9>+TZT`?RN?\&^$EYX2_:]_:F^'=O=&?2;;X7ZR;
MDJY>&YO/`7Q8TO0M*NH]C!-OD^(=9(.WE;I0FQ00T?\`P4WLKW]A?_@J]\%?
MVLM)MKFV\(?$&]\.?$/6KBS1@+[^PKS2O!7Q=TN.")46741X<ETV[=00)%\3
MJQ#"-P>V_P"#</X=ZS?^.OVEOC=JD9EL8_#OAKX:VFJL-L>HZWKVLOXL\3K&
M2<N5&B:*S-W:?KGK]\_\%ZO@5_PM/]C.'XCV=E]H\1?`OQCIOB]#&B>9#X<\
M301^%?$UOYQ&X0L\VG2.H.&-JA8$JI`!^V]AJEIJFG6>JZ9<0:C8:C90ZEIM
MW:R+);ZC875O'<V=S:S!B&AEBGA9&R00X(X(K\&/^#@+]H>3X>_LS^$O@1HM
MTY\5_'GQ65N;"R8F\;P3X*^R:EJDQ2.0OB?Q%?>'+6%-F9F28+G:0OUE_P`$
M@/CA_P`+Q_8/^$$MS?+>^(OAAI\OPDUO?)++/#<>"/)MM$:XD9MTB/X:?P^>
MN2#@DGD_D+XI;_AX%_P7!TC0V:/5_A7^S%<V$,D3L;O3O[.^#]U/JVK;UF.R
M>"]^(^IB,,!^_1"3N6-10!^Y_P"QA\";C]D[]AKP#\-+FQ73_&'ASX::MXK\
M9QQ*/.C\?:_IEYXGU^*6=%4SW5MJ%Z;3S,DD6(P<;:_!+_@W8TN#Q+\?OVI_
MB+J6VY\0)X%T""*>X_>213>,?&6I:QJL\:OEEWW&DVJL0WW5`.22:_K&U>P7
M5=,U'2IV$<6IV-UITIR"-M_:W%M,$X^]F;OUP*_D._X(K^(F_9X_X*(_M`_L
MZ>+V32KOQ5I_B_X?:?;71:,3:_\`#SQ5J6IZ9#"Z<//-X=T_7I,GC"#D4`?V
M%4444`1.`6!RP*QN00./O(01QRP*+[>H.:_D$_8"LX/AU_P7(^-W@_P]&MGH
MLOC/]HCP\MI;K^Z33/M5]JL-HP3`6!+RUMG`P"'C/-?UTZ[J]AH&DZEK>JW4
M5CI>CV-SJFI7<SA4MM/L();N\F?/\`@@?Z_A7\C7_!'E;G]HG_@J'^T%^T=8
MQ[_#MI:?%/QRMYO!1KCXA^++G2O#MOD\L)-(O9)^/[GH#33M?S`T_P!@*(>/
M_P#@NI^TKXCUUEN;OPSX\_:CETMI")BA\/\`BC5/`-@5,@8+)'I%T@B*X*K"
M,?+Q7]<X0*<C@D`'@#..F<#MS_WT:_CE\"^(HOV.?^"\GC1_%[+I7AOXF?%G
MQK:37K';"FG?'G3]0UKP_J#JG#0CQ%J^EKW^>0$YQ7]B\;%B<DG:&!/\+-O9
M#@=L&,_]]T2=[65K`2TW+`G(XSQ@<G_Q[^G:G5_-S_P6S_:[_:0_9S^/'[-W
MA;X)?%?Q)\/]$\8^#]6O_$>F:&UMY6K7<'C&SL(KB>.:)BTBV<CQC!`VMCK2
M`_;7]L=2_P"R3^TX@X+?`/XMKR">#X$UT-T/'RYYZ#J00,'^/G_@EM_P5'\'
M?L"?#WXI>$?$GPB\6_$=_B'XUTGQ5:W_`(;UW2],M]+2P\-6>DO87)U"R87$
MK"..161E.`_R8'R_V"?ME?\`)H_[3QY!'P!^+I!!(((\!Z\0>/<"OPI_X-R_
M"?A;Q!\$_P!I*YU[PUX?UJX@^+OAJW@GU;1M.U&6"`^!-.F,$,EY;.88?-ED
M;:I"[G)QF@#9_P"(D/X3_P#1KOQ0_P#"S\,?_(%?K'^P+^W+H'[>GPL\6?%+
MPY\/=>^'%EX5^(][\/)-(\1ZI9ZK=W\UGX7\,>)3JL%S8VL4:0,OB:.$)AR'
MLG^?+87ZX_X5K\.O^A!\%?\`A*Z%_P#(%;ND>'M`\/PRVV@Z'I&B6\]P;N>W
MT?3;/3()KMHHX&N9H;*%%EN###$F]@6VQ*N<*``#^6+_`(./!GQY^R/GMIWC
M@_\`?.K>'2/PR*_<#]JK]E[2_P!K_P#8EO?@U=_8X?$&J_#KPWK7@75K]5,&
MB^.M$T&UO?#]_+)C,%L]RIM[A@1^XO'!RN5/X@?\''?_`"/O[(__`&#?'7_I
MU\/5_3Y\/_\`DGW@+IC_`(0[PQNR2!M&AV);..VT&@#^=W_@@M^U+K>GGXD_
ML'_%A+[0/'?PRU3Q-X@\!:%K\K)J=G8:=JXT_P"(7@*=)2,:IHVO2)<A0-T\
M>I7\J`QV35]7?\%Z&W_\$_\`7W_O?$GX>D9!4X-])U5AE&]0>0>.U?F]_P`%
M=?A/XT_8@_;-^$'_``4+^#-I);Z9XJ\5:7<^*H;2,_8(OB+X?TV[MM2TK5D@
MVYL?$OA*:_WDY\R33-0=_FD)K[5_X+"?%;PC\<_^"5N@_%GP)?)?^%/B!XG^
M%'B#1Y$<R30KJ,[R-IMQ(>MY;W`GMY_^FMNPH`^PO^"//_*.S]G'_L!^(_\`
MU+]>K]-J_,G_`((\_P#*.S]G'_L!^(__`%+]>K]-J`"HI0"`",]>GTQW^OZ5
M+3'Z#Z_Y_E1IUU#39JZ>Z[KL?-O[57P#T/\`:6^!?CWX0:VL5O/XBTB2?PUJ
MLJ[FT/Q9I6+KPSKD9520(=56U\P`;FA,BC[QK^$3QMX.U_P!XO\`%'@CQ/I\
MFF>(/">O:GX?U?3Y.MK?:;>RVCP(`3^Z(C5H0,EHF1ERO-?Z)#*'QNQP-H)S
MGDY8$@?=^5,?0U\-_%O_`()V?LB_&SQ]KGQ)^)'POCUKQAXB%J-8U.U\1^*M
M&6\-K:-912O9Z1JL,/VO[.Y!G$:R$JI8D@&OON#.,J?#GUNCCE.M@\1:48QU
ME&HK+2[LHN-[KO;4_F/Q]\#\;XFSR7,N'ZF&P>>9?>A5J8BHZ4*N&:;BI.%*
MI*52G-15/9<DIWNTC^'3!]#^1H(?*@8!9U4!@3DE@,J`"69?O``$DH,`FO[2
M!_P27_8*8@#X,S$^G_"<>.^?_*\/YTD__!)']@YDPOP5E`8,CX\=>/AO1E*X
MW#Q(,,21@C.,9'(%?=Q\5<BDY6PM=::7Y-^E_>6GH?S<_H@^)#IU)+.,JC)<
MO*E5Q%2[;7-=K#QM:.RMOU>Q^2G_``2_^&7A3]GOX/?%C_@H-\8+-ETWPQH6
MMZ#\*;&^#-)?2V\8M-7U#39K@!%U34]5NH=)MVW#Y1<[L)&[+^,OQ8^)7B7X
MQ_$?QE\4O&-T]UXE\::_>:YJ+\XMXY;EY;33+3CY(8+,6T"`XPMN!7[_`/\`
MP6@\$^)OA/\``'X`_#'X8Z!8>&?V;=%U>;2-9L=)\R00^(M/T^8^$++61<,?
M]!&G0:O.EPSL9K\.;@^8\!?^<!G\QGE*LGFL\K*ZLI5YG\R3*.`4.]V.TX*\
M*0,8KV>$9+-HYGQ55?/B,P;PT$W=TL.FDJ<>SO=OU/B_&VE5X,_L/PKP].2R
M_A6A3K8FI9J.,QF/LJ]9.T.=1IOV-)N'-"/-U=QE'K[_`.>?6BBOM;:)=OT/
MP=QNK)V6GX.XC#*X(WK\Q*!C&6_=30NCR#D*T=RVW'0H2<9&?W8^!=VG_!07
M]@?Q?^SEK,Z7W[0'[,EF/$OPE>]9)+[Q3X=LK:=]*MK&=V#?:1%]JTB=2%78
M]B2WESRE/PHK[]_X)CW7Q-M?VT/@]_PK&*.6ZO=2N+3Q?#<22PV4GP_\ASXN
M^WRQJ2D,>FB.[B."IN["SB!S(PKYOBW">VRJOF-.:H8K*N6M"=[-<LE%I/\`
MO)M/R;/TWPHS7ZGQ13R7$X:6/R7B]QR[%X:$>9S6*G&G1JPCJE+#UW3KJ332
M=.[32/@65'@DEAG1K>:!VBG@G!AGAF2:2W>*:&3#1S+/')&ZD!D="K`$$5'D
M>H_,?XU_9U\0O^"3/['7Q0\>>*?B'XD\)^*[37/&NK7.MZR/#_CGQ#HFGRZE
MJ$K75\\&F6EUY-I%)?&:Y=44?OYV(.TA:Y'_`(<L?L.?]"]\2.W_`#5#Q1^/
M_+:OFEXJ9(U%XJE5^L.,.;EM:ZBD][Z_UL?K.*^B)XET\9C(Y=B\NJX"-6<*
M+KXB=*HX0ERJ4HQI5$W.W.VG%7;]U'\>N5QDLH&X9RZ`*"K,6;)^50%.6.%7
M')%?U`?\$6/V2V\&>`M;_::\8V*)XE^(T,^@?#V"X1"='\"V4I74-71G7,5_
MJNIQ2KN4_)9:9"`1]HE6OHC_`(<L_L/!E)\.?$*5`\;O#<_$SQ3+`ZHQ,D4B
M"Z4212*55U/4(`".2?U&\,^&-(\(^'M&\*^'[*'3="\/Z19Z-I%G#GR;:QLH
M([>W@4,<E5AB098EFQECDDGY3C#Q`P><Y7++\KA.DJSO.4DN:RZ1MIJ[)WZ'
M[#X'?1PS[@KBQ\2\9RPN*65T_:8&G0G[6$,4[)U.:48MM+9J,==EH=(NX`9S
MCY>?H1SCL/\`/2OY*/VLI8Q_P<%_!8^9$=WC'X#%0LB,[;/`M@Q41J2V_:R$
M+C+!OE!K^MEEW(4."&7:P.<%3PPX[[<XKX/\=_\`!.C]GOXC?M5>&?VQO$A\
M>CXQ>%-2\,:KI0TSQA+8^$S=>$K"#3])%[H`T]A>Q""VA#@R+OP>1W_+#^T6
MKV=[6/NZ`YC'7C`.0000HR,$5^37_!8S]D7_`(:D_9-\0:IH.D#4/B7\$I+_
M`.)7@B2*)7O[RQL[&)?&/AJV549IH;SP_!+-Y8R[W6AVJHK-M4_K/&GEJ%XX
MSC:-J@=@%R<#'O[]ZBDB:0D,0$W@C!.2G[LNKJ00X8JZG/\`"Y%`S_/;_:._
M::3]H;]B/]E/PMXAU62?XA_LY^(/'_PRU2"ZFWSW7@#5=#\/7?PWU**:0Y>*
M"#2=7TB5CA6CT&S(XVLW][/P:^;X/?"@+N)/PU\!<HVT[3X8TO+HW0X$J'^7
M(Q7Y;^+?^"#_`.P5XN\6^)O%\ND?%/0KGQ3KVH^(KC1O#'Q!71O#FDWFI7MQ
M?3VN@Z5#H#?V;IBRW=PL4`D9(8F\N/:I-?K[X7\.V'A+P[H/A?2C,=+\.:)I
M.@:=]IE,UT;'1M/M]-M#=3G_`(^+C[/;1[GP,D=*`/Y(O^"D_P"S7\:O^">_
M[7^G?\%`?V>M/DA\`>)?%TGC'Q!<:1;23:1X/\:ZVS0^-M!\56T2@V?A#73J
M.IRK<R/Y#RW\@G,<EI`)?VC_`&3_`/@KS^Q_^TEX:TB/7OB1X7^"GQ-^Q1+K
MWPZ^)>KVGA[RM0\I!-)X7\1ZE+!8^(M%:<R?92DBW+Q*K/;ID%OU`UW0-%\3
MZ5J&A>(=*TW6]$U:U>RU/2=6LK?4-/O[63.ZWN[2[C>.>(Y/#(W)R,$`U^-7
MQN_X(,_L0?%G5+O7?"T'Q!^".I7DK7%Q9?#7Q!8R^%;NXDF,TLMQX:\7:1J7
MV)BS/C^S+G30"^0N<[@#]$?'W[9O[)?PVT6XUKQO^T=\'-!T^&(2_/X_\/7E
M_=#&Y8M/TK3+Z:[U*=@,"*VAEE;)"KFOYG_V^O\`@H9X^_X*3>*="_8Q_8I\
M(>)=<\#Z]X@TY?$.MWEC<:5?^/;RUN'>Q&KVA`D\(?#>T+QW=Q)J!BNKA+%)
M#&N%1ON+PE_P;B?LFZ1?K=>*_B_\=O%EFCASI%E=^`?"UG=`-Q#?7$'@F[N&
MAV%@?L\MM)TVR+7Z_P#[._['?[.?[*>B'1?@3\+O#W@KS8UBOM:1+G5/%.JQ
M@1[DU+Q3J\\]]/&\D43O'YPA9HQB)0```<;^P5^R1H'[%W[-_@OX-:;<PZOX
MA@2;Q!\0/$D$9CA\0^.=;2";7;^V5P&.GHT-O:VI8!WMM.A=P&)`^@/C!\,]
M&^,OPN^(?PG\3QLWA[XC>$?$/@S4W15D>UM-?TF>P&HQ1LZ@W-M<RQS1#.-\
M`R.X])BC\M`N0<8Y`"CH!@*.%4`8`[``5)0!_%5_P3:_:XU?_@GS:_M_?!KX
MH3VVE^*/!'@OQEKGA+39Y5:WG^-/PMUFX\#3:7813G-Q:7=WKEC>1*FY9;30
MYC'O(45^FO\`P;[?L_7N@_"+XL?M3>,8I+KQA\=?%]WH6@ZC<_O;@>#?!VI7
M5QJFH+=;OFDU;QIJ.HRS`95AX=MF4D+D_7OQR_X(Q_L9?M!_%SQA\:O'=A\2
M;/QEXZU.WU;Q"GA7QR-!T6XO[6&*);Z/3HM#<K<RO$\D^)`KR7<I.<BOT0^"
MWP?\&_`3X7>!OA!\/;.:P\&?#WP_;>&]`MKNY:^OFLK5F<7-]?.B&YO9IY+B
M:=RHWS73D8&!0!Z<Z$DL"V?DP!@[=A8_*#W.X@^U?RP_\%C_`-BKXJ?!SXVZ
M/_P46_9CCU"UN=*U#P_K/Q+BT&TFN=2\$^+O#)C_`+)^(,-K`A$_@N[TV*.W
MUBW;,4=S"UPY6.[F9/ZHZHWEA!J$4]K>V]K=V=U!):W5K=PK=07-K.A2>WEM
MY@8VB88W*RNL@&&7@4`?C9^Q/_P6=_9J_:#\*Z+I7QI\8^&O@3\9+>VBT[7M
M%\67)T3P1K>KP;EN[[PGXLU*3[+;13/ADTR_G@O[<95EN,>8/T4\4_M>?LJ^
M#]%FU_Q/^T?\$-%T>&)IVOKSXG>#A&ZJC,!;I%K!DNI3CY(X5>23&$4FO@W]
MH/\`X(@_L,?'O4[[Q%:>%_%'P7\3ZC,]U>:I\']:L]'TZ\N7Q_Q]^%/$.DZE
MI(AR`2;6RM)R1GSP,@_+?AS_`(-P?V7--U*.YUWXZ?'W6=/1MSZ?IK?#?0)K
MA>-T-QJ/_"#73-"P^]Y<<3\`JZ%10!\W?\%(?^"KH_:@L'_8X_89T_Q-XXD^
M)URGA/Q9X^TO2M0TZX\6:=>L%D\,>!=+U"%;N/2IS(/[1U.XB@5;9R,)`%FF
M_7W_`();_L,K^Q+^SQ#H'B2VLY?B_P#$F^L_&?Q7U.T,<@MM1-L%T?P;;7:C
M_2--TBUN9H5/S*UQ>7[QLRRJS^X?LS_L$_LM_LBP,_P/^&&E:'KTUHMI=^--
M:EN_$GC:]3"K()O$>K32306\@7]Y!;"WB<D_*`<5]C*"%`8@MCYB`0">Y`).
MT9Z#)P.,F@#\`O\`@M)_P3E\3_M&:!H_[2?P-TBYO/C/\,+%++Q#H&G7$=IJ
M7C+P38W+ZA8ZAH<D461XLT6^5I[>/.+BU.T'SHU5O!_^"?\`_P`%R/!VF^%=
M`^#7[:S:OX5\5^%+=/#EA\8FT?4;[2]4MK!8[:RB\?Z);PR7^B>(8TA=)9XH
MIEG\KS)(XSES_3JP)'&,Y!&>!P0>>#Q_GCK7Y[_M*_\`!+[]C?\`:JU"\\0_
M$KX76FE>-]1$IOOB!\/+N?P1XMNKB08%U?7%@)+76Y@"W_(2M+WD@@C;M(!Z
M]X?_`&XOV./$6FQ:KI/[4'P*GL9HA.LMQ\3_``K8/$I17*7-OJFIPRV4P!R8
MI420!@2@W"OYA/\`@N?\;/@_\;/VE/V8;GX/_$_P)\3[?PWX1U#3M=G\">*-
M(\4PZ7?7_CBPFL[6ZET:[F59I(E+``G`&6VY&?T&NO\`@V^_90DU'SK+XY?M
M&V6E;\IIK7_PIN;N.,G+1KJO_"KD++Z?N!R22237T?\`"G_@A1^P3\,;RSU3
M4/#OQ%^*FJZ;<0WEA<_$KQT]Q:6]U!*)TD.A^#])T?3KD><J'%Q:7&-@Y)H`
M^_OVRO\`DT?]I[K_`,D`^+HX!/7P%KPR<#A?4G@#DD`$U_.W_P`$"?VE/V>_
M@7\&?V@--^,WQL^%WPMO]?\`BOH.H:)9^//&_A[PQ/JUC:^"M.LKB[T]-6OX
MOM4"W4;H63/*Y'RD$_U#?$/P/HGQ.\`^-?AQXE^U_P#".^/?"NO^#M=^P7!M
M+XZ/XDTNZTC4A:705OL]R;.\FV/@[6(.#C%?CK_Q#_?L"[F)3XVYW,RO_P`+
M1+3'>D,;*\TOAYF9-EM!A<X!!XZ&@#[W_P"'A7["?_1X/[-__AXO`O\`\NZ[
MOX=?M=?LM_%[Q+#X.^%?[0GP>^(WBNXM;N]@\.>"?B!X:\3:S+:V,2S7DZ:?
MH^HS2F..)U9CMX!K\SO^(?\`_8&]/CA_X=(?_,Y7T!^S'_P25_91_9*^*]A\
M9/A,GQ*'C'3=,UK1;9O$_CEM<TS^SO$%E!::AY^GOI$8EN0(<QL&0+GD'N`?
MD%_P<>R1IX^_9(#R1QD:9XZ8^9(D?`U7P_TWL-Q^4],_J,_U"?#KCP!X$4D9
M'@SPUQGDXT73\D>HY'(XYKY(_:\_X)Y_`#]MO5?`6L?&M?&QO/AM!J-OX9'@
M_P`5R>'+<+JEQ9W5T=0MUL)A=`RV4("[A\GREJ^UM'TFWT33=-TFS:7[%I.F
MV6E62RR%W^RV,$=M`9F(_>SB&&(%^-QR=HS0!\W_`+9?[-WA[]K']G?XC?`_
MQ!'!')XJT82^&=6E3<_A_P`::7<PWOA/6T9?F2*#5XX3,0"?(:4`$G!_BFL_
MCSXF\+?L0?M+?L"?%\76D^)?AC\3?#WCKX<V5Y(3<6&HZ3XPAT3XA>"+%)#E
M;%)IK?5;)8=^]9+YE+&2$/\`W],@8Y8`@!<<D'(8-SCH`RH1]#7Y7_M$?\$=
MOV.?VF?BYXE^-7Q`TOX@Z7XS\7MILGB`>"O&J^'-'O[G3;!+'[;)IQT2?_3K
MA$C^TS!U:3R48;2""`;G_!'@@_\`!.S]G':0P&A^)/F0AT/_`!6&O+\LBDJW
M(/0GU''-?IO7BO[/WP'\$_LU?";PA\%_ANVM?\(7X)M[NTT8>(M5DUS66M[J
M]O+Y_MNJ211FY?[1=L?N#&,9/6O:J`"D(!&#2T4`,\L=B?YTH7'\3?@<4ZBB
MR>ZN`PID$;FY]3G],5&+=/XOG]`P']!4]%--I66@K>\I7:<=K-K\$['@7[27
MP.\-_M"_!OQU\)/$\2-I_BK1)(;"Z,<+R:1K]FYN]`UFV$T+JMQ;:O'8RC*.
MKB`HZLK%3_!S\1O`/B7X4>.?%?PX\8VK67BGP9KEYX>U>W=9$DDO;)W/VI(Y
MB7-M<VD;3P.7;*RJ2S<Y_P!#R5E!(.00I.0,]B>GKUQ]*_FV_P""VG[)X27P
M_P#M7^"M/_=7+V?@_P"+,$$2!#(L1M/!WBN=E4&%0)]2L[LG+.\E@3]PU^D^
M&_$$L%F+RK&5''!XV:<+O13T2^;2[[I:,_D;Z5_AM+B#AJGQIE%%5,ZX<C'Z
MQ"W\7`1E>I6EK=RPU^:%OYG>]C^=>E&._P#G\/6DZ4H]/Q/KQG_&OWMSB[6F
MM;=5W/\`.-4*L[1A"7,[<NCUDM8QVVD[1?DV-)"JS,0%!!)`)*(J2O(S^N=J
M!<8Y)SGC']6'_!&7]E(?"[X47_[0/BW3PGCCXM0"W\.BYC=;GP_X`MIE$2)'
M*=UO<:CJ%B;J8YPUM8VB(B'S6E_`W]AO]F:__:J_:(\&_#@6]P?"MI<1^)_B
M)?QF:-+/P5H=U;3W]JL\8_=75_+(EC#)UAFOHWYW5_<WH^DZ9H6DZ7H^D6<5
MCI>CV=IINGV5M&(8+6SM(([>TABB4#8BV\4:A<?*$V]*_*/$OB*-*$,AP\N6
M5:TJC3W@EI%^LK/Y?(_LWZ)/AI4S#-,3Q_FM!.AEDY4\"I)_[TTO;))VTHKF
MA%V=N:^ZNME5`()/)(&!@C<!P1],U-M'TYST'X=JA5<E,'HQ8$Y&0PS^?2IZ
M_$91BWT;TOH?Z#07N1;TD[MJ[LG?7\1NT9ZG&,8X`Y.>P]12%`<\D9].@P<\
M?Y[T^BA:;:%62^3O\P'``]****!A1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`PH"P;.#_GO6#K^@:/XCL+G1M>T;3-=TJ]0QWFF:U96>I:7=1<8C
MNK&^@EBN%_V7C85O,&)X.!]2/Y4@3GGI[?\`ZJ:;333U1G4I0K1<*L5.#Z/8
M\;/[/_P3R?\`BS?PGZG_`)IQX,/Z_P!@\TO_``S_`/!$`E_@U\*3TV[?AUX.
M0@\YY71!D8^M>P^4/1?UI1'CT'TST].:TCB\1=+V]3Y[=.VO],X/[%RA:K+<
M.WY4*4?Q2NO7<X3PU\-_`/@J>YN?!_@/PAX5FO(HHKZ;PWX=T309[N&%W>*&
MY?2K*%KN(.[$)(Q0$[@`2<]Y$"$&>N6/)!QECCD`<8P![<4%.P`(/J3G]*>!
M@`?R_P#KUG*52<W.<W)_UW;.RC0I4(\E'#PH0[15OOM_6@M%%%(W"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
B***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
